First Tracks Biotherapeutics Inc
NASDAQ:TRAXBiotechnology
-$0.89 today
- Market cap
- $1.87B
- Beta
- 0.00
- P/E (TTM)
- -6.1
- EPS (TTM)
- -$2.81
Volume 0.75M
Average 0.43M
TRAX Cash & Equivalents
Cash on hand and highly liquid investments that can be converted to cash almost immediately.
First Tracks Biotherapeutics IncNASDAQ: TRAX
Cash & Equivalents · Q1 FY2026 · quarter ended Mar 2026
Cash & equivalents remains negative
Q1 FY2026 cash & equivalents was $248.47M, compared with $0 a year earlier.
Context
- Cash & equivalents amounted to 85.5% of total assets at the end of Q1 FY2026.
- Cash & equivalents increased in 2 of the last 2 fiscal years.
- FY2025 was the highest annual figure in the 3 fiscal years shown.
Sources:Balance SheetText generated from reported figures; not investment advice.
Cash & Equivalents history
USD · from the balance sheet
- Latest · FY2025
- 238.2M USD
- Year-over-year change
- +93.5%
- 2-year CAGR
- +157.4%
| Period | Period end | Cash & Equivalents | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 238.2M | +93.5% |
| FY2024 | 2024-12-31 | 123.08M | +242.2% |
| FY2023 | 2023-12-31 | 35.97M | — |
Cash & Equivalents vs competitors
How TRAX compares with its peers on the latest reported figures
- TRAX's Mar 2026 cash & equivalents of $248.47M is the 3rd highest of the 10 companies compared; the peer median is $32.83M.
- Cash & equivalents amounts to 85.5% of total assets for TRAX, versus a peer median of 25.6%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Sep 2026 | $722.27M | +38.4% | +33.8% | 94.9% | |
| Mar 2026 | $298.49M | +9.9% | +103.8% | 74.6% | |
TRAXFirst Tracks Biotherapeutics Inc | Mar 2026 | $248.47M | — | — | 85.5% |
| Mar 2026 | $248.47M | +151.9% | +49.5% | 75.4% | |
| Mar 2026 | $186.63M | +1204.7% | -47.5% | 98.4% | |
| Jun 2026 | $32.83M | — | — | 25.6% | |
| Mar 2026 | $28.66M | -5.6% | -23.9% | 14.4% | |
CLYMClimb Bio, Inc. | Mar 2026 | $8.36M | -71.2% | -6.4% | 5.5% |
| Jun 2026 | $8.27M | +123.9% | -11.3% | 3.5% | |
| Mar 2026 | $6.15M | -27.6% | -26.1% | 4.2% | |
ODTXOdyssey Therapeutics, Inc. | — | — | — | — | — |
| Peer median (excluding TRAX) | $32.83M | +24.2% | -8.9% | 25.6% | |
Competitors are the stored peer set for TRAX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
First Tracks Biotherapeutics Inc
NASDAQ:TRAX
Intrinsic Alpha fair value
Locked
Current Price
$44.50
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.